> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Outlook Resubmits ONS-5010 BLA
- URL: https://www.fdaweb.com/outlook-resubmits-ons-5010-bla/
- Published: 2022-08-30T12:00:00.000Z
- Updated: 2026-09-14T17:57:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152629

Outlook Therapeutics says it has resubmitted to FDA a BLA for its ONS-5010 (Lytenava) (bevacizumab-vikg) to treat wet age-related macular degeneration. Company officials [say](https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-re-submits-biologics-license-application?ref=fdaweb.com) they have worked for the past three months to provide the additional information FDA required that was not in the 3/2022 BLA submission and to address agency requests to ensure that the BLA is complete for acceptance and review.

ONS-5010 is described as an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection to treat wet age-related macular degeneration and other retinal diseases.